New Study Investigates the Utility of Masimo SpHb® in Post-operative Red Blood Cell (RBC) Transfusion Best Practices
Masimo (NASDAQ: MASI) announced today the findings of an abstract presented at the 2018 Annual Meeting of the Network for the Advancement of Patient Blood Management, Haemostatis and Thrombosis (NATA), in which researchers investigated the utility of Masimo noninvasive and continuous hemoglobin (SpHb® ) in supporting and enhancing red blood cell (RBC) transfusion best practices as part of post-operative patient blood management (PBM).1
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180419005949/en/
In the study, Prof. Baricchi and colleagues in the Transfusion Medicine Unit, AUSL-IRCCS of Reggio Emilia and at the Department of Medicine and Surgery at the University of Parma, Italy, sought to evaluate the appropriateness of post-operative RBC transfusion over a three-year period (2013-2015), before and after implementation of a patient blood management (PBM) program. The PBM policy consisted of three months of training followed by the introduction of noninvasive, continuous point-of-care (POC) monitoring of patient hemoglobin using Masimo SpHb on Masimo Radical-7® Pulse CO-Oximeters® . An initial audit of RBC transfusion appropriateness was conducted prior to the introduction of the PBM policy, on 168 patients. A final audit, after the policy was in place, was conducted on 205 patients. To determine transfusion appropriateness, investigators used the guidelines established by the Italian Society of Transfusion Medicine and Immunohaematology (SIMTI).
The researchers found that prior to the introduction of the PBM policy, 37.7% of RBC transfusions were appropriate. After the introduction of the PBM policy, including use of noninvasive and continuous hemoglobin monitoring with Masimo SpHb, they found 65.4% of RBC transfusions were appropriate, a significant increase in transfusion appropriateness.
The researchers concluded that, “In our experience, the PBM strategies introduced improved RBC transfusion appropriateness in the post-operative period. We believe that our PBM policy and introduction of POC testing are a valuable support for the healthcare workers in the transfusion decision-making process. This enhancement of transfusion appropriateness implies clinical and managerial advantages, such as reduced transfusion-related risks, optimization of the health care resources and reduction of the costs.”
SpHb is not intended to replace laboratory blood testing. Clinical decisions regarding red blood cell transfusions should be based on the clinician’s judgment considering among other factors: patient condition, continuous SpHb monitoring, and laboratory diagnostic tests using blood samples.
@MasimoInnovates | #Masimo
- Baricchi R, Marraccini C, Merolle L, Berni P, Bonini A, Mazzi A, Pertinhez T.A., and Di Bartolomeo E. Patient blood management: transfusion appropriateness in the postoperative period. Proceedings from the 2018 NATA Annual Meeting, Lisbon, Portgual. #P30.
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive monitoring technologies. Our mission is to improve patient outcomes and reduce the cost of care. In 1995, the company debuted Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms. Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,1 improve CCHD screening in newborns,2 and, when used for continuous monitoring with Masimo Patient SafetyNet™* in post-surgical wards, reduce rapid response activations and costs.3,4,5 Masimo SET® is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world,6 and is the primary pulse oximetry at 17 of the top 20 hospitals listed in the 2017-18 U.S. News and World Report Best Hospitals Honor Roll.7 In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb® ), oxygen content (SpOC™), carboxyhemoglobin (SpCO® ), methemoglobin (SpMet® ), Pleth Variability Index (PVi® ), and more recently, Oxygen Reserve Index (ORi™), in addition to SpO2 , pulse rate, and perfusion index (Pi). In 2014, Masimo introduced Root® , an intuitive patient monitoring and connectivity platform with the Masimo Open Connect® (MOC-9® ) interface, enabling other companies to augment Root with new features and measurement capabilities. Masimo is also taking an active leadership role in mHealth with products such as the Radius-7® wearable patient monitor, iSpO2 ® pulse oximeter for smartphones, and the MightySat™ fingertip pulse oximeter. Additional information about Masimo and its products may be found at www.masimo.com . Published clinical studies on Masimo products can be found at http://www2.masimo.com/evidence/featured-studies/feature/ .
ORi has not received FDA 510(k) clearance and is not available for sale in the United States.
*The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.
- Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
- de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.
- Taenzer AH et al. Impact of Pulse Oximetry Surveillance on Rescue Events and Intensive Care Unit Transfers: A Before-And-After Concurrence Study. Anesthesiology. 2010; 112(2):282-287.
- Taenzer AH et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter . Spring-Summer 2012.
- McGrath SP et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety . 2016 Jul;42(7):293-302.
- Estimate: Masimo data on file.
- http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview .
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo SpHb® . These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including Masimo SpHb, contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov . Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
CA-TRUE-RELIGION19.10.2018 19:39 | pressemeddelelse
Manchester United and True Religion Launch Denim Range
ARCH-INSURANCE19.10.2018 15:12 | pressemeddelelse
Arch Insurance Announces Strategic Leadership Changes
MA-TAKEDA-PHARMACEUTICAL19.10.2018 14:02 | pressemeddelelse
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
VERTEX-PHARMACEUTICALS19.10.2018 13:56 | pressemeddelelse
Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene
TX-SCHLUMBERGER-LIMITED19.10.2018 13:02 | pressemeddelelse
Schlumberger Announces Third-Quarter 2018 Results
CA-TRADESHIFT19.10.2018 13:02 | pressemeddelelse
Tradeshift Announces Q3 2018 Results
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum